StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 9.4
Power Rank trend -> Rising
07/08/2024 10:33:00 EST
Sarepta Therapeutics Inc (SRPT)
Industry: Biotechnology
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, SRPT has been trading in a range between $163.85 and $116.83 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
SRPT is trading below resistance at $163.85, about 8% to the upside. There is support at $127.94 -16% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Sarepta Therapeutics Inc $SRPT entered a Green zone 10 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $180.61, a potential upside of 19.03% from the recent price of 151.73. The stock is trading 14.18% (potential upside) below its 52 week high of $173.25 and 174.62 % (potential downside) above its 52 week low of $55.25 - based on the recent price.
Company Summary
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
News
| After a Big Win, Is Sarepta Therapeutics Stock a Buy? Sarepta Therapeutics just received expanded labeling for one of its therapies. But the therapy has not performed as well as expected in clinical trials. Source: The Motley Fool Sat, 06 Jul 2024 08:00:00 -0400 Sentiment: Positive |
| Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News? Previously, Sarepta's gene therapy treatment Elevidys was approved for only a limited number of Duchenne muscular dystrophy patients. Regulators, however, have expanded that range, and it can now be used to treat patients who are 4 and older. Source: The Motley Fool Thu, 04 Jul 2024 06:35:00 -0400 Sentiment: Positive |
| Best Momentum Stocks to Buy for July 3rd SRPT and ASYS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 3, 2024. Source: Zacks Investment Research Wed, 03 Jul 2024 11:00:41 -0400 Sentiment: Positive |
| 1 Soaring Growth Stock to Buy and Hold for 10 Years Sarepta Therapeutics' most important medicine now looks even more promising. The biotech's financial results are improving substantially. Source: The Motley Fool Wed, 03 Jul 2024 10:05:00 -0400 Sentiment: Positive |
| New Strong Buy Stocks for July 3rd MONDY, MWA, SRPT, ASYS and CLCO have been added to the Zacks Rank #1 (Strong Buy) List on July 3, 2024. Source: Zacks Investment Research Wed, 03 Jul 2024 07:50:34 -0400 Sentiment: Positive |
Technicals 52 Week Hi: 173.25 52 Week Low: 55.25 Beta: 0.884 50 Day MA: 132.5596 200 Day MA: 116.518 Earnings / Revenue Trends Qtr Earnings Growth YOY: 0 Qtr Revenue Growth YOY: 0.631 Forward PE: 35.2113 Trailing PE: 361.2619